Penicillamine carries one of the highest side-effect burdens of any drug still in regular clinical use. In studies of patients with rheumatoid arthritis, over half of treatment courses were complicated by at least one adverse reaction, and roughly a quarter to a third of patients had to stop the drug entirely because of toxicity. The range of problems it can cause is unusually broad, spanning the skin, kidneys, blood, lungs, and immune system. For people taking penicillamine for Wilson disease, cystinuria, or other conditions, understanding what to watch for and when to worry is genuinely important.
How Often Do Side Effects Happen?
The short answer is: frequently. A prospective three-year study of 259 patients with rheumatoid arthritis found that 58% of treatment courses involved at least one reaction, and 27% of courses had to be stopped because of side effects.1PubMed. Adverse effects of D-penicillamine in rheumatoid arthritis A separate retrospective review of 156 patients reported a 62% rate of toxic reactions, with 36% needing to stop the drug.2PubMed. Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis Another chart review of 63 patients put the overall complication rate at 53%, including life-threatening problems like aplastic anemia and nephrotic syndrome.3The American Journal of Medicine. Toxicity of D-penicillamine in rheumatoid arthritis
Those numbers come from rheumatoid arthritis populations, where penicillamine has largely been replaced by newer drugs precisely because of its toxicity profile. In Wilson disease, where penicillamine remains a first-line treatment, the picture is somewhat better but still notable. A retrospective audit of 112 patients with hepatic Wilson disease found that about 25% developed intolerance to the drug, and more than half of those who reacted had to permanently stop taking it.4PubMed. Adverse Events with D-penicillamine Therapy in Hepatic Wilson’s Disease: A Single-Center Retrospective Audit The lower rate in Wilson disease patients likely reflects the different doses used and the younger, otherwise healthier population being treated.
Skin Rashes and Early Reactions
Skin problems are the single most common side effect. In the large prospective rheumatoid arthritis study, rashes appeared in 44% of treatment courses.5PubMed. Adverse effects of D-penicillamine in rheumatoid arthritis These early rashes are often itchy, mildly raised eruptions that show up within the first few weeks of treatment. Many are allergic in nature and resolve if the drug is temporarily stopped and reintroduced at a lower dose. A smaller fraction of patients develop mouth sores (stomatitis), which appeared in about 10% of courses in the same study.
More concerning are the autoimmune blistering diseases penicillamine can trigger. The drug has been linked to pemphigus vulgaris and pemphigus foliaceus, conditions where the immune system attacks proteins that hold skin cells together, causing painful blisters and erosions. Researchers have noted that the “late scaling rash” sometimes seen with penicillamine may actually represent early pemphigus that gets mistaken for something milder.6PubMed. Penicillamine-induced pemphigus A high proportion of patients who develop penicillamine-induced pemphigus carry the HLA-B15 tissue type, suggesting a genetic predisposition.
Long-Term Connective Tissue Damage
Penicillamine’s effects on skin go beyond rashes. The drug interferes with collagen cross-linking by reacting with the chemical intermediates that hold collagen fibers together.7PubMed. Collagen cross-linking. Effect of D-penicillamine on cross-linking in vitro This is actually one of the reasons it was used for systemic sclerosis, a disease of excessive collagen deposition. But in patients taking it for years, especially at high doses, that same mechanism can damage elastic tissue throughout the skin.
The two classic connective tissue complications are cutis laxa and elastosis perforans serpiginosa. Cutis laxa means the skin loses its elasticity and hangs loosely, giving a prematurely aged appearance. Elastosis perforans serpiginosa produces ring-shaped or serpentine patches of small bumps where abnormal elastic fibers are being expelled through the skin surface. Both conditions are rare but well documented in patients on long-term, high-dose penicillamine, particularly those being treated for Wilson disease.8PubMed Central. Penicillamine-induced Elastosis Perforans Serpiginosa and Cutis Laxa in a Patient with Wilson’s Disease The two can even occur together in the same patient, though that combination is exceptionally uncommon.9Skin Health and Disease. Coexisting elastosis perforans serpiginosa and acquired cutis laxa following long-term penicillamine in Wilson disease
Other elastic tissue abnormalities linked to long-term use include pseudo-pseudoxanthoma elasticum, which mimics the yellowish skin papules of a genetic disorder, and anetoderma, where small patches of skin become depressed and baggy.10PubMed Central. Penicillamine-Induced Localised Cutis Laxa in a Patient with Wilson Disease: A Case Report These connective tissue effects develop gradually over months to years and may not fully reverse even after stopping the drug.
Kidney Problems
Penicillamine can provoke an immune-mediated attack on the kidneys, usually showing up as protein in the urine. Proteinuria was reported in 7% to 14% of rheumatoid arthritis patients across different studies.11PubMed. Adverse effects of D-penicillamine in rheumatoid arthritis 12PubMed. Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis The underlying kidney damage is typically membranous glomerulonephritis, a condition where immune complexes deposit along the filters in the kidneys. A detailed study of 33 rheumatoid arthritis patients who developed proteinuria during penicillamine treatment found membranous glomerulonephritis on biopsy in 29 of them.13British Medical Journal. Natural course of penicillamine nephropathy: a long term study of 33 patients
In most cases, the proteinuria resolves after penicillamine is stopped, though recovery can take months. In severe cases, kidney damage can progress to nephrotic syndrome, where massive amounts of protein leak into the urine, causing swelling and other systemic problems. This is why routine urine testing is standard for anyone on penicillamine. Catching protein leakage early, before it becomes severe, usually means the kidneys recover fully.
Blood Cell Abnormalities
Some of the most dangerous side effects of penicillamine involve the blood. The drug can suppress the bone marrow’s ability to produce blood cells, and depending on which cell lines are affected, this can lead to different problems. Thrombocytopenia (low platelets, increasing bleeding risk) and leukopenia (low white cells, increasing infection risk) are the more common hematologic effects, occurring in roughly 2-3% and 2-11% of patients respectively across various studies.14PubMed. Adverse effects of D-penicillamine in rheumatoid arthritis 15PubMed. Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis
The rarest and most feared blood complication is aplastic anemia, where the marrow essentially shuts down production of all cell types. A case report described a 22-year-old man with Wilson disease who developed profound pancytopenia four months after starting penicillamine. Bone marrow biopsy showed hypocellularity across all three cell lines, and the condition resolved only after stopping the drug.16PubMed. D-Penicillamine Induced Myelotoxicity: A Unique Case Other documented hematologic side effects include hemolytic anemia, where the drug triggers destruction of red blood cells.17Korean Journal of Hematology. A Case of Aplastic Anemia Induced by D-penicillamine Because blood count drops can be sudden and severe, regular blood monitoring is not optional when taking this drug.
Autoimmune Diseases Triggered by Penicillamine
Penicillamine has a peculiar ability to provoke entirely new autoimmune conditions. The best documented is drug-induced myasthenia gravis, a neuromuscular disease where the immune system produces antibodies against the receptors that nerve signals use to communicate with muscles. This causes progressive muscle weakness, drooping eyelids, difficulty swallowing, and in severe cases, breathing problems. A systematic review confirmed the association, with diagnosis typically supported by the presence of antibodies against acetylcholine receptors in the blood.18PubMed Central. D-Penicillamine-Induced Myasthenia Gravis-A Probable Complication of Wilson’s Disease Treatment-A Case Report and Systematic Review of the Literature
The mechanism appears to involve penicillamine’s reactive sulfhydryl group, which can chemically modify proteins on cell surfaces. This modification changes the way the immune system “sees” the body’s own tissues, potentially tricking immune cells into attacking them. Research has shown that penicillamine can alter the shape of immune molecules involved in antigen presentation, particularly in people carrying the DR1 tissue type.19PubMed. T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes This same general mechanism likely underlies the drug’s ability to trigger pemphigus and other autoimmune conditions. The encouraging news is that drug-induced myasthenia gravis often improves significantly or resolves completely once penicillamine is stopped, unlike the idiopathic form of the disease.
Loss of Taste and Digestive Complaints
Dysgeusia, a distortion or complete loss of taste, is one of penicillamine’s more distinctive side effects. It was reported in about 20% of patients in the large prospective study, making it the second most common reaction after rashes.20PubMed. Adverse effects of D-penicillamine in rheumatoid arthritis The taste disturbance is thought to be related to penicillamine’s ability to chelate zinc, a trace element essential for normal taste perception. In most patients, taste returns on its own after a few weeks even without stopping the drug, though some people find food remains “metallic” or “flat” for months.
Gastrointestinal upset is also common, with nausea, vomiting, and appetite loss affecting roughly 12-18% of patients across studies.21The American Journal of Medicine. Toxicity of D-penicillamine in rheumatoid arthritis These symptoms are most pronounced early in treatment and often improve with dose adjustment or by taking the drug on an empty stomach, away from meals. They are annoying but rarely dangerous on their own.
Vitamin B6 Depletion
Penicillamine interferes with vitamin B6 metabolism. It reacts chemically with pyridoxal-5′-phosphate, the active form of B6, and may also inhibit the enzyme that produces it.22PubMed. Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs Studies in rheumatoid arthritis patients on penicillamine confirmed that markers of B6 function were markedly reduced compared to what would be expected.23Biochemical Pharmacology. The effect of penicillamine on vitamin B6 function in man B6 deficiency can cause symptoms of its own, including nerve tingling, mouth sores, confusion, and anemia. For this reason, most prescribers recommend supplemental pyridoxine (typically 25 mg daily) alongside penicillamine. This is standard practice but worth confirming with your doctor, because the recommendation is sometimes overlooked.
Neurological Worsening in Wilson Disease
For patients taking penicillamine specifically for Wilson disease, a paradoxical neurological worsening is one of the most feared early complications. When penicillamine begins mobilizing copper from the liver into the bloodstream for excretion, there can be a transient spike in free copper levels. In patients who already have neurological symptoms from copper deposits in the brain, this surge can make things dramatically worse: tremors intensify, speech deteriorates, walking becomes more difficult.24European Neurology. Worsening of Wilson Disease following Penicillamine Therapy Some patients never fully recover the ground they lose during this initial worsening.
This risk is the main reason some Wilson disease specialists prefer to start with a different chelator (trientine) or with zinc therapy in patients who present with neurological symptoms. Predictors of who will worsen have been studied but remain imprecise. The safest strategy is gradual dose escalation with close neurological monitoring in the first few months.
Lung Complications
Bronchiolitis obliterans is a rare but well-recognized pulmonary complication of penicillamine. The condition involves inflammation and scarring of the small airways in the lungs, leading to progressive shortness of breath and cough. It has been reported primarily in patients taking penicillamine for rheumatoid arthritis or systemic sclerosis.25PubMed. Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine Because both rheumatoid arthritis and systemic sclerosis can themselves cause lung disease, it can be tricky to pin the blame on penicillamine with certainty. But the temporal pattern in case reports, where lung function deteriorates during treatment and stabilizes after stopping the drug, supports the connection.
Who Is More Likely to React?
There is genuine evidence that genetics play a role in penicillamine toxicity. Research in rheumatoid arthritis patients found that certain immune system tissue types are strongly associated with specific side effects. Patients carrying HLA-B8 and HLA-DR3 were at substantially increased risk of developing proteinuria, with a relative risk of about 4 to 14 times that of patients without those markers.26PubMed. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis A separate study confirmed this link, finding that nearly all patients who developed heavy proteinuria during penicillamine treatment carried DRw3.27PubMed. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis Interestingly, patients with these same genetic markers were also more likely to react to gold therapy, suggesting a shared underlying immune predisposition to drug toxicity.
Non-kidney side effects followed a different pattern: HLA-B7 and HLA-DR2 were associated with skin and other non-nephrologic reactions.28PubMed. HLA antigens and toxicity to gold and penicillamine in rheumatoid arthritis These associations are not routinely tested for before starting penicillamine in clinical practice, partly because the drug is now used in a narrower range of conditions and partly because HLA typing was expensive when these findings were published. With genetic testing now cheaper and more accessible, there is an argument for revisiting whether pre-treatment HLA typing could flag high-risk patients.
Penicillamine Compared to Trientine
For Wilson disease patients, the main alternative chelator is trientine. The safety comparison between the two matters a great deal because treatment for Wilson disease is lifelong. A phase 3 trial comparing trientine tetrahydrochloride to penicillamine for maintenance therapy found that penicillamine was associated with three serious adverse events (leukopenia and two cancers), while trientine had none. The most common non-serious side effect with penicillamine was headache, occurring in about 19% of patients compared to 8% on trientine.29PubMed. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial
A broader analysis of adverse event reports submitted to the FDA found that penicillamine and trientine have distinct safety profiles. Trientine may be better suited for women of childbearing age because of fewer immune-related adverse events, while penicillamine may be better tolerated in patients who have gastrointestinal problems with trientine.30PubMed Central. Safety of penicillamine and trientine in the treatment of Wilson’s disease: An analysis of the FDA Adverse Event Reporting System (FAERS) database Overall, adverse events leading to treatment discontinuation are significantly more frequent with penicillamine than with trientine.31Clinical Gastroenterology and Hepatology. Efficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease Despite this, penicillamine remains widely used because it is cheaper, more widely available globally, and has decades of clinical experience behind it. For many patients in low-resource settings, it is the only option.
Desensitization When Penicillamine Cannot Be Avoided
Some patients develop allergic reactions to penicillamine but have no practical alternative. This is particularly relevant in severe Wilson disease where liver function is deteriorating and the patient needs a chelator urgently. In these situations, desensitization protocols can work. A case report described a 16-year-old with severe hepatic Wilson disease who developed a serious allergic reaction to penicillamine. She was placed on a liver transplant waiting list because her disease was too severe to leave untreated. Doctors then gradually reintroduced penicillamine in tiny, escalating doses, successfully desensitizing her immune system so that medical therapy alone was sufficient and transplant was avoided.32PubMed. Penicillamine hypersensitivity: successful desensitization of a patient with severe hepatic Wilson’s disease
Desensitization is not appropriate for all types of reactions. It works best for straightforward allergic-type responses like rashes and hives. It should not be attempted for the more serious immune-mediated complications like blood count drops, kidney damage, or autoimmune diseases triggered by the drug. In the Wilson disease audit mentioned earlier, just under half of patients who had temporary reactions were successfully reintroduced to penicillamine, sometimes at a reduced dose.33PubMed. Adverse Events with D-penicillamine Therapy in Hepatic Wilson’s Disease: A Single-Center Retrospective Audit The decision to rechallenge always involves balancing the severity of the original reaction against the severity of the disease being treated.
What Monitoring Looks Like in Practice
Given the breadth and unpredictability of penicillamine’s side effects, monitoring is intensive compared to most medications. During the first several months, most protocols call for complete blood counts and urine protein checks every one to two weeks. After the patient has been stable for a while, testing frequency typically drops to monthly. Any new symptom, whether it is easy bruising, swelling in the legs, muscle weakness, persistent mouth sores, or a new rash, warrants prompt blood and urine testing.
Patients are generally told to report taste changes (even though they are usually self-limiting), because they can occasionally signal zinc depletion that needs attention. Skin changes that develop gradually over years, like increasing looseness or unusual bumps, should also be brought up, since the connective tissue effects of long-term use are easy to overlook until they become significant. For Wilson disease patients specifically, early neurological worsening during the first weeks of treatment needs immediate evaluation, because the treatment itself may be making things worse rather than better.